Pfizer Collaborates with Beam on Gene Editing Technology
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 1 (Table of Contents)
Published: 20 Jan-2022
DOI: 10.3833/pdr.v2022.i1.2656 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Starting 2022 in earnest, Pfizer has agreed to collaborate with Beam Therapeutics to develop gene editing therapies for rare genetic diseases of the liver, muscle, and central nervous system...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018